{"id":"fov1101-00","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Fovea Pharmaceuticals' FOV1101-00 is designed to address inherited retinal dystrophies and age-related macular degeneration by promoting photoreceptor cell survival and function. The drug works through intracellular signaling modulation to protect against photoreceptor degeneration. The exact molecular target and detailed mechanism remain proprietary, but the approach focuses on neuroprotection in the retina.","oneSentence":"FOV1101-00 is a small molecule that targets retinal degeneration through modulation of cellular survival pathways in the eye.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:00:38.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inherited retinal dystrophies"},{"name":"Age-related macular degeneration"}]},"trialDetails":[{"nctId":"NCT01120132","phase":"PHASE2","title":"Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Fovea Pharmaceuticals SA","startDate":"2010-05","conditions":"Allergic Conjunctivitis","enrollment":716},{"nctId":"NCT00833495","phase":"PHASE2","title":"Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation","status":"COMPLETED","sponsor":"Fovea Pharmaceuticals SA","startDate":"2009-01","conditions":"Allergic Conjunctivitis","enrollment":155}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"FOV1101-00","genericName":"FOV1101-00","companyName":"Fovea Pharmaceuticals SA","companyId":"fovea-pharmaceuticals-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOV1101-00 is a small molecule that targets retinal degeneration through modulation of cellular survival pathways in the eye. Used for Inherited retinal dystrophies, Age-related macular degeneration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}